325 related articles for article (PubMed ID: 26974310)
1. PTEN opposes negative selection and enables oncogenic transformation of pre-B cells.
Shojaee S; Chan LN; Buchner M; Cazzaniga V; Cosgun KN; Geng H; Qiu YH; von Minden MD; Ernst T; Hochhaus A; Cazzaniga G; Melnick A; Kornblau SM; Graeber TG; Wu H; Jumaa H; Müschen M
Nat Med; 2016 Apr; 22(4):379-87. PubMed ID: 26974310
[TBL] [Abstract][Full Text] [Related]
2. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
Gomes AM; Soares MV; Ribeiro P; Caldas J; Póvoa V; Martins LR; Melão A; Serra-Caetano A; de Sousa AB; Lacerda JF; Barata JT
Haematologica; 2014 Jun; 99(6):1062-8. PubMed ID: 24561792
[TBL] [Abstract][Full Text] [Related]
3. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
Ramírez-Moya J; Wert-Lamas L; Santisteban P
Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
[TBL] [Abstract][Full Text] [Related]
5. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability.
Silva A; Yunes JA; Cardoso BA; Martins LR; Jotta PY; Abecasis M; Nowill AE; Leslie NR; Cardoso AA; Barata JT
J Clin Invest; 2008 Nov; 118(11):3762-74. PubMed ID: 18830414
[TBL] [Abstract][Full Text] [Related]
6. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
[TBL] [Abstract][Full Text] [Related]
7. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.
Gutierrez A; Sanda T; Grebliunaite R; Carracedo A; Salmena L; Ahn Y; Dahlberg S; Neuberg D; Moreau LA; Winter SS; Larson R; Zhang J; Protopopov A; Chin L; Pandolfi PP; Silverman LB; Hunger SP; Sallan SE; Look AT
Blood; 2009 Jul; 114(3):647-50. PubMed ID: 19458356
[TBL] [Abstract][Full Text] [Related]
8. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
9. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
11. Common Genomic Aberrations in Mouse and Human Breast Cancers with Concurrent P53 Deficiency and Activated PTEN-PI3K-AKT Pathway.
Martinez JD; Mo Q; Xu Y; Qin L; Li Y; Xu J
Int J Biol Sci; 2022; 18(1):229-241. PubMed ID: 34975329
[TBL] [Abstract][Full Text] [Related]
12. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
13. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
15. Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers.
Nakahata S; Ichikawa T; Maneesaay P; Saito Y; Nagai K; Tamura T; Manachai N; Yamakawa N; Hamasaki M; Kitabayashi I; Arai Y; Kanai Y; Taki T; Abe T; Kiyonari H; Shimoda K; Ohshima K; Horii A; Shima H; Taniwaki M; Yamaguchi R; Morishita K
Nat Commun; 2014 Feb; 5():3393. PubMed ID: 24569712
[TBL] [Abstract][Full Text] [Related]
16. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
17. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
18. Antibody to human α-fetoprotein inhibits cell growth of human hepatocellular carcinoma cells by resuscitating the PTEN molecule: in vitro experiments.
Ohkawa K; Asakura T; Tsukada Y; Matsuura T
Int J Oncol; 2017 Jun; 50(6):2180-2190. PubMed ID: 28498467
[TBL] [Abstract][Full Text] [Related]
19. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
Goltsov A; Faratian D; Langdon SP; Mullen P; Harrison DJ; Bown J
Cell Signal; 2012 Feb; 24(2):493-504. PubMed ID: 21996585
[TBL] [Abstract][Full Text] [Related]
20. Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.
Beckham TH; Cheng JC; Lu P; Marrison ST; Norris JS; Liu X
PLoS One; 2013; 8(10):e76593. PubMed ID: 24098536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]